Vaxcyte to Present at Guggenheim 2nd Annual Vaccine and Infectious Disease Conference

Rhea-AI Summary

Vaxcyte, Inc. (Nasdaq: PCVX) announced participation in a fireside chat at the Guggenheim 2nd Annual Vaccine and Infectious Disease Conference on October 5, 2021, at 11:30 am ET. A live webcast will be available through the Company’s website, with a replay accessible for 30 days post-conference. Vaxcyte focuses on developing novel vaccines to combat infectious diseases, featuring advanced technologies like the XpressCF™ platform. Their lead candidate, VAX-24, targets invasive pneumococcal disease.

FOSTER CITY, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced that Company management will participate in a fireside chat at the Guggenheim 2^nd Annual Vaccine and Infectious Disease Conference on Tuesday, October 5, 2021 at 11:30am ET.

A live webcast of the presentation can be accessed through the Investors & Media section of the Company’s website at http://investors.vaxcyte.com. A replay of the webcast will be available for approximately 30 days following the conference.

About Vaxcyte
Vaxcyte is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide. The Company’s cell-free protein synthesis platform, comprising the XpressCF™ platform, exclusively licensed from Sutro Biopharma, Inc., together with Vaxcyte’s proprietary know-how, enables the design and production of protein carriers and antigens, the critical building blocks of vaccines, in ways that the Company believes conventional vaccine technologies currently cannot. Vaxcyte’s lead vaccine candidate, VAX-24, is a preclinical, 24-valent broad-spectrum pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease. Vaxcyte’s pipeline also includes VAX-XP, a PCV with an expanded breadth of coverage of at least 30 strains; VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; and VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease by targeting the keystone pathogen responsible for this chronic, oral inflammatory disease. For more information, visit www.vaxcyte.com.

Contacts:
Andrew Guggenhime, President and Chief Financial Officer
Vaxcyte, Inc.
650-837-0111
investors@vaxcyte.com

Janet Graesser, Vice President, Corporate Communications and Investor Relations
Vaxcyte, Inc.
917-685-8799
media@vaxcyte.com 

FAQ

What event will Vaxcyte participate in on October 5, 2021?

Vaxcyte will participate in the Guggenheim 2nd Annual Vaccine and Infectious Disease Conference on October 5, 2021.

At what time is Vaxcyte's presentation scheduled on October 5, 2021?

Vaxcyte's presentation is scheduled for 11:30 am ET on October 5, 2021.

How can I access Vaxcyte's webcast during the conference?

The live webcast of Vaxcyte's presentation can be accessed through the Investors & Media section of their website.

What is Vaxcyte's lead vaccine candidate?

Vaxcyte's lead vaccine candidate is VAX-24, a preclinical 24-valent broad-spectrum pneumococcal conjugate vaccine.

What is the purpose of Vaxcyte's vaccine development?

Vaxcyte aims to develop superior vaccines to prevent or treat common and deadly infectious diseases worldwide.